| Title: |
Incidence and Risk Factors of Venous Thromboembolic Events in Patients with ANCA-Glomerulonephritis: A Cohort Study from the Maine-Anjou Registry |
| Authors: |
Henry, Nicolas; Brilland, Benoit; Wacrenier, Samuel; Djema, Assia; Garnier, Anne Sophie; Gansey, Renaud; Coindre, Jean-Philippe; Besson, Virginie; Duveau, Agnès; Subra, Jean-François; Cousin, Maud; Piccoli, Giorgina Barbara; Augusto, Jean-François |
| Contributors: |
Henry, Nicola; Brilland, Benoit; Wacrenier, Samuel; Djema, Assia; Garnier, Anne Sophie; Gansey, Renaud; Coindre, Jean-Philippe; Besson, Virginie; Duveau, Agnè; Subra, Jean-Françoi; Cousin, Maud; Piccoli, Giorgina Barbara; Augusto, Jean-François |
| Publication Year: |
2020 |
| Collection: |
Università degli studi di Torino: AperTo (Archivio Istituzionale ad Accesso Aperto) |
| Subject Terms: |
ANCA glomerulonephriti; risk factor; statin; venous thromboembolism |
| Description: |
(1) Introduction: The incidence of venous thromboembolisms (VTE) has not been extensively analyzed in patients with antineutrophil cytoplasmic antibody (ANCA)-glomerulonephritis (ANCA-GN). Thus, the aim of the present study was to assess the frequency and the risk factors of VTE in patients with ANCA-GN. (2) Methods: Patients from the Maine-Anjou ANCA-associated vasculitis (AAV) registry with a biopsy showing pauci-immune glomerulonephritis were included. VTE events, site, and interval from AAV diagnosis were analyzed. (3) Results: 133 patients fulfilled the inclusion criteria of the study and were analyzed. VTE episodes were diagnosed in 23/133 (17.3%) patients at a median delay of 3 months from ANCA-GN diagnosis. Patients with VTE had lower serum albumin (p = 0.040), were less frequently on statin therapy (p = 0.009) and had less frequently proteinase-3 (PR3)-ANCAs (p = 0.078). Univariate analysis identified higher age (p = 0.022), lower serum albumin (p = 0.030), lack of statin therapy (p = 0.009), and rituximab treatment (p = 0.018) as significant risk factors of VTE. In multivariate analysis, only lack of statin therapy (HR 4.873; p = 0.042) was significantly associated with VTE. (4) Conclusion: Patients with ANCA-GN are at high risk of VTE, especially within the first months following AAV diagnosis. Our results suggest that statin therapy is associated with a lower risk of VTE in ANCA-GN patients. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/33007967; info:eu-repo/semantics/altIdentifier/wos/WOS:000586258800001; volume:9; issue:10; firstpage:1; lastpage:11; numberofpages:11; journal:JOURNAL OF CLINICAL MEDICINE; http://hdl.handle.net/2318/1771049; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85096926970; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599765/ |
| DOI: |
10.3390/jcm9103177 |
| Availability: |
http://hdl.handle.net/2318/1771049; https://doi.org/10.3390/jcm9103177; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599765/ |
| Rights: |
info:eu-repo/semantics/openAccess |
| Accession Number: |
edsbas.828F8AFF |
| Database: |
BASE |